Despite a slight uptick in earnings per share, CDW Corporation's stock has plummeted over 38% in three years, starkly underperforming a surging market and leaving investors questioning the disconnect between financial performance and share price.
On-chain data reveals a notable shift in crypto whale activity, with large-scale accumulation emerging in Shiba Inu, Pendle, and Cardano. This strategic positioning coincides with early technical signals hinting at potential rebounds, setting the stage for a pivotal February.
While Exelon's recent earnings beat expectations, the utility giant continues to face investor skepticism over its long-term growth trajectory. Wall Street maintains a guarded optimism, but the stock's performance tells a more nuanced story.
The restaurant chain Steak 'n Shake has announced it will contribute $1,000 to tax-advantaged investment accounts for employees' newborns, aligning with a growing corporate trend to supplement the federal 'Trump Accounts' program aimed at generational wealth building.
Despite posting a Q4 net loss, ArcBest is streamlining operations and investing in technology, positioning for a market rebound while the broader LTL sector continues its slow climb from a prolonged slump.
While rising crude prices have lifted Occidental Petroleum's stock recently, a mixed earnings performance and a predominantly 'Hold' rating from Wall Street signal lingering skepticism about its near-term trajectory.
From post-IPO darling to a stock trading near historic lows, Rivian faces a critical five-year window. With new models on the horizon and a major Volkswagen partnership, analysts see a path to growth—if it can navigate fierce competition and persistent losses.
In a significant policy shift, Chinese authorities have reportedly cleared the AI startup DeepSeek to purchase Nvidia's advanced H200 processors, potentially easing a major hardware bottleneck for its competitive large language model.
As SpaceX targets a record-shattering IPO for mid-2026, reports indicate Elon Musk is exploring a potential merger with either Tesla or his AI startup, xAI. The move could create a unified tech and industrial behemoth but faces significant regulatory and operational hurdles.
BlackRock has increased its stake in the diversified precious metals miner Sibanye-Stillwater beyond 5%, signaling strong institutional confidence amid a historic rally in gold and platinum group metals. We examine the drivers behind the surge and what it means for investors.
French biopharma firm Inventiva (ENXTPA:IVA) has delivered a stunning 126% total return to shareholders over the past year, sharply contrasting with losses over a three-year horizon. As the stock experiences short-term pullbacks, analysts debate whether its current €5.23 price reflects future promise or present hype, with a key drug candidate hanging in the balance.
Verizon Communications posts its strongest customer gains since 2019, bolstered by a key fiber acquisition and a renewed strategic focus under CEO Hans Vestberg, signaling a potential inflection point for the telecom giant.
With Spirit Airlines shrinking operations under bankruptcy protection, JetBlue executives confirm detailed contingency plans are ready to deploy, centering on the crucial Fort Lauderdale hub.
Longtime CMO Jon Bridges steps down as Chick-fil-A enters its 80th anniversary year. Michael Lage, a 14-year company veteran with digital and operations experience, will take the helm after a transition period.
American Express reported fourth-quarter earnings that slightly trailed analyst forecasts, prompting a share price decline. Despite the near-term miss, the company issued strong forward guidance for 2026 and announced a significant dividend hike, underscoring confidence in its long-term growth trajectory driven by card member spending and fee growth.
Morgan Stanley and Barclays have both lowered their price targets for Appalachian Basin natural gas leader Antero Resources (AR), citing revised commodity forecasts. Despite the cuts, Morgan Stanley maintains an 'Overweight' rating, signaling continued confidence in the stock's long-term trajectory.
Regeneron Pharmaceuticals is positioning its experimental obesity drug, olatorepatide, as a potential game-changer by combining significant weight loss with a dramatic reduction in 'bad' cholesterol. The company believes this dual benefit could carve out a unique niche in the competitive $150 billion market, currently led by Novo Nordisk and Eli Lilly.
Amidst a choppy market, value investors are hunting for bargains. We spotlight three companies—Dingdong, Origin Bancorp, and ATRenew—whose current share prices appear significantly disconnected from their estimated intrinsic value, presenting potential opportunities for the discerning investor.
Amid a cautiously optimistic market backdrop, companies where executives hold significant stakes are drawing investor attention. We examine three such firms where insider buying and strategic moves signal confidence in long-term growth.
While major indices hold steady, a search for growth is turning the spotlight onto smaller companies. We examine three small-cap stocks—from insurance to banking to luxury watches—that are posting strong results and navigating unique challenges in the current market.
